Drug Discovery Outsourcing

Drug Discovery Outsourcing Market Outlook

The global drug discovery outsourcing market is projected to reach USD 78.9 billion by 2035, growing at a compound annual growth rate (CAGR) of 8.6% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing pressure on pharmaceutical companies to reduce costs and improve the efficiency of drug development processes, as well as the rising demand for innovative therapies amid the growing prevalence of chronic diseases. Furthermore, the rising adoption of advanced technologies such as artificial intelligence and machine learning in drug discovery is expected to further accelerate market expansion. The shift towards personalized medicine and the need for faster drug approvals are also driving an increase in outsourcing activities, as companies seek to leverage specialized expertise and advanced infrastructure provided by service organizations.

Growth Factor of the Market

One of the primary drivers of the drug discovery outsourcing market is the escalating costs and complexities associated with drug development. Pharmaceutical companies are increasingly outsourcing various phases of drug discovery to specialized organizations that offer high-end expertise, advanced technologies, and a streamlined approach to research and development (R&D). This enables them to focus on their core competencies while reducing overhead costs, improving time-to-market, and accelerating the overall drug development process. Additionally, regulatory pressures and the need for compliance have compelled companies to partner with contract research organizations (CROs) that have extensive knowledge of the nuances of regulatory submissions. The growing trend of collaborations between pharmaceutical companies and CROs or contract manufacturing organizations (CMOs) is also intensifying as firms seek to enhance their competitive edge through innovative and efficient drug development strategies.

Key Highlights of the Market

• Rapidly growing preference for outsourcing due to cost efficiencies and specialized expertise.
• Increased investment in drug discovery outsourcing by pharmaceutical and biotechnology companies.
• Growing adoption of advanced technologies like AI and machine learning in drug discovery processes.
• Expansion of service offerings by CROs and CMOs to meet evolving market demands.
• Rising prevalence of chronic diseases driving the need for accelerated drug discovery efforts.

By Service Type

Contract Research Organizations:

Contract Research Organizations (CROs) are pivotal in the drug discovery outsourcing landscape as they provide essential services throughout the drug development process. These organizations offer a broad spectrum of capabilities including preclinical research, clinical trial management, data management, and regulatory support. The demand for CRO services is primarily driven by pharmaceutical and biotechnology companies aiming to minimize costs and mitigate risks associated with drug development. By outsourcing these functions, companies can access specialized expertise, cutting-edge technology, and a more flexible workforce. Moreover, the trend towards global trials and the need for faster patient recruitment further enhance the significance of CROs, making them an indispensable partner in the quest for new therapeutics.

Contract Manufacturing Organizations:

Contract Manufacturing Organizations (CMOs) play a critical role in the drug development ecosystem by providing manufacturing services for pharmaceutical products. The outsourcing of manufacturing processes allows companies to maintain focus on their core R&D activities while leveraging the established production capabilities of CMOs. This segment is increasingly vital as the complexity of drug formulations evolves, especially with the rise of biologics and personalized medicines. CMOs offer expertise in large-scale production, quality assurance, and regulatory compliance, which is crucial for ensuring the safe and timely availability of drugs in the market. As a result, the CMO segment is experiencing significant growth, driven by increasing global demand for efficient and scalable manufacturing solutions.

Contract Development and Manufacturing Organizations:

Contract Development and Manufacturing Organizations (CDMOs) provide an integrated solution that combines both development and manufacturing services. This dual approach is increasingly attractive to pharmaceutical companies aiming for streamlined operations and reduced time-to-market. CDMOs offer services ranging from process development, scale-up, and production to packaging and regulatory support. Their expertise in managing the entire lifecycle of drug development makes them an essential partner, especially for companies looking to innovate and bring new treatments to market quickly. The growth of biologics and complex drug formulations has further propelled the demand for CDMO services, as these require specialized capabilities that many companies may lack in-house.

Contract Sales and Marketing Organizations:

Contract Sales and Marketing Organizations (CSMOs) provide crucial services that assist pharmaceutical companies in promoting and selling their products. By outsourcing sales and marketing functions, companies can gain access to specialized expertise, advanced marketing strategies, and established sales networks without the high overhead costs of maintaining an in-house team. CSMOs play a significant role in helping companies penetrate new markets and drive product awareness, especially for new drug launches. The increasing complexity of the pharmaceutical landscape, coupled with the demand for personalized marketing strategies, has led to the growth of CSMOs as valuable partners in the commercialization phase of drug development.

Other Service Types:

In addition to the major service types discussed above, the drug discovery outsourcing market encompasses various other services including consulting, clinical trial management software, and data analytics. These services contribute significantly to enhancing the efficiency and effectiveness of drug development processes. For instance, consulting services provide strategic insights and guidance on market access, regulatory compliance, and clinical trial design, while clinical trial management software aids in optimizing trial operations and data collection. Furthermore, data analytics services support decision-making by providing valuable insights derived from extensive data analysis. The integration of these additional services into the outsourcing framework is becoming increasingly prevalent, reflecting the multifaceted nature of modern drug development.

By Drug Type

Small Molecule Drugs:

Small molecule drugs represent a significant segment of the drug discovery outsourcing market, primarily because they have been the cornerstone of pharmaceutical therapy for decades. These drugs, characterized by their low molecular weight and ability to easily penetrate cells, are often utilized in the treatment of a wide array of conditions, including chronic illnesses and infectious diseases. The development of small molecules involves intricate synthesis processes and requires advanced analytical techniques, making outsourcing an attractive option for many companies. By collaborating with CROs and CDMOs, pharmaceutical firms can leverage specialized expertise to optimize the discovery and development process, reduce time-to-market, and manage costs effectively.

Biologic Drugs:

Biologic drugs, which are derived from living organisms, are gaining immense traction within the pharmaceutical industry due to their targeted mechanisms of action and potential for treating complex diseases such as cancer and autoimmune disorders. The complexity associated with the development of biologics, including challenges in manufacturing and regulatory compliance, often leads companies to outsource various stages of the drug development process. Contract Research Organizations and Contract Manufacturing Organizations with specialized capabilities in biologics are increasingly sought after to provide the necessary expertise and infrastructure. As the demand for biologic therapies continues to rise, the outsourcing aspect of biologics development is anticipated to expand significantly over the coming years.

Other Drug Types:

The classification of "Other Drug Types" encompasses a variety of therapeutic agents beyond small molecules and biologics. This segment includes gene therapies, vaccines, and advanced therapeutic medicinal products, which have emerged as critical components of modern medicine. The development of these drug types often involves highly specialized techniques and requires adherence to stringent regulatory guidelines. As such, many companies are now turning to outsourcing as a strategy to access the necessary expertise and facilities for development and manufacturing. The increasing focus on innovative therapies is expected to drive growth in this segment, as companies seek to capitalize on emerging opportunities in the evolving pharmaceutical landscape.

By Therapeutic Area

Oncology:

The oncology therapeutic area is one of the most significant and fast-growing segments within the drug discovery outsourcing market. With the increasing incidence of cancer worldwide, pharmaceutical companies are under immense pressure to develop effective treatments swiftly. Outsourcing is becoming commonplace in oncology drug development as companies seek to leverage the advanced capabilities of CROs for preclinical and clinical trial phases. These organizations play a crucial role in patient recruitment, trial design, and regulatory submissions, allowing sponsors to expedite the development process. Additionally, the growing trend of personalized medicine in oncology further fuels the demand for specialized outsourcing services capable of supporting the development of targeted therapies.

Infectious Diseases:

Infectious diseases remain a critical focus area in drug discovery, particularly in light of global health challenges such as pandemics and antibiotic resistance. The urgency for developing effective vaccines and therapeutics has led to an increased reliance on outsourcing for research and clinical trials. Pharmaceutical companies are collaborating with CROs and other specialized organizations to enhance their drug discovery efforts in this domain, benefiting from their expertise in infectious disease research, trial management, and regulatory affairs. The increasing investment in public health initiatives and the urgency to address emerging infectious threats further underscore the importance of outsourcing in accelerating the development of innovative solutions.

Cardiovascular Diseases:

Cardiovascular diseases continue to be a leading cause of morbidity and mortality globally, prompting an urgent need for novel therapeutic interventions. The complexity of developing cardiovascular drugs, which often involves extensive clinical trials and long-term studies, has led many pharmaceutical companies to outsource various aspects of their drug development processes. By collaborating with CROs that specialize in cardiovascular research, companies can optimize clinical trial designs, access diverse patient populations, and ensure adherence to regulatory standards. The growing focus on preventative therapies aimed at cardiovascular conditions is expected to drive the demand for outsourcing services in this therapeutic area.

Central Nervous System Disorders:

The treatment of central nervous system (CNS) disorders, including neurological and psychiatric conditions, poses unique challenges due to the intricacies of brain biology and the need for innovative therapeutic approaches. Outsourcing is increasingly employed in the CNS therapeutic area as pharmaceutical companies seek specialized expertise in neuropharmacology and advanced methodologies for clinical trials. The need for tailored patient recruitment strategies and specialized assessment tools further enhances the reliance on CROs with a proven track record in CNS drug development. Given the rising global burden of CNS disorders, outsourcing in this area is likely to see significant growth as companies strive to develop effective treatments.

Other Therapeutic Areas:

The classification of "Other Therapeutic Areas" encompasses various health conditions that may not fit neatly into the aforementioned categories. This may include rare diseases, metabolic disorders, and conditions affecting the musculoskeletal system, among others. The drug discovery process for these therapeutic areas often involves unique challenges, including limited patient populations and specialized regulatory pathways. As a result, pharmaceutical companies are increasingly turning to outsourcing as a means to access the expertise and resources required for successful drug development. The ongoing focus on rare disease treatments and the need for innovative therapies within these less common therapeutic areas are anticipated to drive growth in the outsourcing market.

By User

Pharmaceutical and Biotechnology Companies:

Pharmaceutical and biotechnology companies represent the largest segment of users in the drug discovery outsourcing market. These organizations often face immense pressures to innovate while managing costs, leading them to rely on outsourcing to enhance their R&D capabilities. By partnering with CROs and CDMOs, these companies can leverage specialized expertise, advanced technologies, and scalable resources that would be costly and time-consuming to develop in-house. The increasing complexity of drug development, coupled with the growing emphasis on personalized medicine and biologics, further intensifies the reliance of pharmaceutical and biotech companies on outsourcing services to expedite their drug discovery and development efforts.

Academic and Research Institutes:

Academic and research institutes are increasingly participating in the drug discovery outsourcing landscape as they often seek to translate their research findings into viable therapeutic solutions. These institutions frequently collaborate with CROs to access specialized capabilities, advanced technologies, and regulatory expertise that may not be available within their own facilities. Outsourcing allows these organizations to focus on their core research activities while leveraging the expertise of external partners, thus accelerating the drug development process. This trend is expected to grow as academic institutions expand their role in translational medicine and seek to contribute to the development of novel therapies.

Others:

This category encompasses a diverse range of users including government organizations, non-profit entities, and other stakeholders involved in drug discovery and development. These users often seek outsourcing solutions for various reasons including access to specialized knowledge, efficient resource allocation, and enhanced collaboration with industry experts. As governmental initiatives increasingly emphasize the importance of public health and innovation in drug development, the demand for outsourcing services from these users is expected to rise. By collaborating with CROs and other service providers, these organizations can enhance their R&D capabilities, contribute to the development of innovative therapeutics, and address public health challenges effectively.

By Region

The drug discovery outsourcing market is experiencing notable growth in North America, accounting for approximately 40% of the global market share in 2025. The presence of a well-established pharmaceutical industry, advanced R&D capabilities, and a significant concentration of leading CROs and CMOs contribute to this dominance. Furthermore, the increasing investment in drug discovery and development, coupled with a focus on innovative therapies, drives the demand for outsourcing services. The North American market is expected to maintain a robust CAGR of 9.2% during the forecast period, reflecting the region's pivotal role in shaping the future of drug discovery outsourcing.

Europe holds a considerable share of the drug discovery outsourcing market, estimated at around 30% in 2025. The region benefits from a strong pharmaceutical sector, extensive research networks, and supportive regulatory frameworks. Countries such as Germany, the United Kingdom, and France are at the forefront of drug development initiatives, fostering collaborations between pharmaceutical companies and outsourcing partners. The European market is projected to grow at a CAGR of 8.1% during the forecast period, driven by increasing investments in biopharmaceuticals and the rising demand for cost-effective drug development solutions. Meanwhile, the Asia Pacific region is also gaining traction as a favorable outsourcing destination due to its growing capabilities and cost advantages.

Opportunities

The drug discovery outsourcing market presents a plethora of opportunities, particularly in the wake of evolving healthcare needs and technological advancements. One of the most pronounced opportunities lies in the integration of artificial intelligence and machine learning in drug discovery processes. These technologies have the potential to significantly enhance the efficiency of R&D by enabling predictive modeling, data analysis, and optimization of clinical trials. Companies that can adeptly incorporate these innovative solutions into their outsourcing strategies stand to benefit from improved drug discovery timelines and more effective allocation of resources. Furthermore, there is a growing trend towards personalized medicine, which is creating demand for specialized services tailored to the unique requirements of individual patient populations. This shift opens up avenues for CROs and CMOs to develop niche offerings that cater specifically to personalized therapies, thereby expanding their market presence.

Additionally, the rise of globalization in the pharmaceutical industry is fostering new opportunities in emerging markets, where there is a burgeoning demand for outsourcing services. Regions such as Asia Pacific and Latin America are becoming increasingly attractive for pharmaceutical companies seeking to leverage cost-effective solutions and access diverse patient populations for clinical trials. CROs and other service providers that establish a strong presence in these regions can tap into the growing appetite for innovative therapies while optimizing their operational costs. Moreover, the increasing focus on collaboration between academic institutions and the pharmaceutical industry provides fertile ground for outsourcing relationships that can accelerate drug development efforts across various therapeutic areas, reinforcing the overall growth trajectory of the drug discovery outsourcing market.

Threats

While the drug discovery outsourcing market holds significant promise, it is not without its challenges and threats. One of the most pressing concerns is the issue of intellectual property (IP) protection, which can deter pharmaceutical companies from engaging in outsourcing arrangements. The risk of potential IP theft or misuse is a significant barrier, particularly when sensitive proprietary information is shared with external partners. Companies must navigate complex legal frameworks and ensure that robust contractual agreements are in place to safeguard their innovations. Additionally, the growing competition among outsourcing service providers can lead to price wars, potentially compromising the quality of services offered. As firms strive to secure contracts, there is a risk that cost-cutting measures may impact the reliability and effectiveness of outsourced projects.

Furthermore, regulatory hurdles represent another obstacle for the drug discovery outsourcing market. The pharmaceutical industry is subject to stringent regulations governing drug development and approval processes, and navigating these regulatory landscapes can be complex. Outsourcing to organizations in different jurisdictions may introduce variability in compliance standards and practices, creating challenges in achieving consistent quality and meeting regulatory requirements. Companies must remain vigilant in selecting outsourcing partners that adhere to the highest standards of quality and regulatory compliance. Lastly, the ongoing evolution of global health landscapes, including the emergence of new diseases and changing treatment paradigms, may necessitate rapid adjustments in outsourcing strategies, adding further complexity to the market.

Competitor Outlook

• Covance Inc.
• Charles River Laboratories International, Inc.
• PPD, Inc.
• IQVIA Holdings Inc.
• Syneos Health, Inc.
• Parexel International Corporation
• Medpace, Inc.
• WuXi AppTec
• Envigo
• Lonza Group AG
• Evotec SE
• Catalent, Inc.
• Clinical Research Services, Inc.
• Pharmaron Beijing Co., Ltd.
• Charles River Labs

The competitive landscape of the drug discovery outsourcing market is characterized by a diverse array of players ranging from large multinational CROs to specialized niche providers. These companies vie for market share by offering a range of services that cater to the evolving needs of pharmaceutical and biotechnology firms. Notably, major CROs like Covance, Charles River Laboratories, and IQVIA possess extensive global networks and deep industry expertise, positioning them as frontrunners in the market. Their ability to provide integrated services from preclinical research to post-market studies enables them to cater to the entire drug development lifecycle, thereby enhancing their competitive advantage. Furthermore, these companies are heavily investing in advanced technologies and innovative methodologies, which play a crucial role in maintaining their market leadership.

In contrast, specialized firms such as Evotec SE and Medpace Inc. focus on niche therapeutic areas or particular phases of drug development. These organizations differentiate themselves by providing highly tailored services and expertise in specific fields, which appeals to pharmaceutical companies seeking specialized solutions. As the market continues to evolve, there is an increasing trend toward strategic partnerships and collaborations, allowing companies to leverage complementary strengths and resources. Through these partnerships, firms can enhance their capabilities, expand service offerings, and ultimately improve their competitive positioning within the drug discovery outsourcing landscape.

As the drug discovery outsourcing market progresses, major players are likely to continue exploring growth opportunities through acquisitions, mergers, and strategic alliances. For instance, companies like Parexel and Syneos Health are actively pursuing expansion strategies to enhance their service portfolios and geographic reach. Additionally, the focus on technological innovation is driving competitive differentiation, as organizations strive to integrate advanced analytics, AI, and machine learning into their outsourcing solutions. This emphasis on innovation not only improves operational efficiency but also enhances the overall quality and effectiveness of drug development processes. As a result, the competitive landscape is expected to remain dynamic, with ongoing shifts and adaptations to meet the changing demands of the pharmaceutical industry.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Envigo
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Evotec SE
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 PPD, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 WuXi AppTec
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Covance Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Medpace, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Catalent, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Lonza Group AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Charles River Labs
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 IQVIA Holdings Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Syneos Health, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Pharmaron Beijing Co., Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Clinical Research Services, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Parexel International Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Charles River Laboratories International, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Drug Discovery Outsourcing Market, By User
    • 6.1.1 Pharmaceutical and Biotechnology Companies
    • 6.1.2 Academic and Research Institutes
    • 6.1.3 Others
  • 6.2 Drug Discovery Outsourcing Market, By Drug Type
    • 6.2.1 Small Molecule Drugs
    • 6.2.2 Biologic Drugs
    • 6.2.3 Other Drug Types
  • 6.3 Drug Discovery Outsourcing Market, By Service Type
    • 6.3.1 Contract Research Organizations
    • 6.3.2 Contract Manufacturing Organizations
    • 6.3.3 Contract Development and Manufacturing Organizations
    • 6.3.4 Contract Sales and Marketing Organizations
    • 6.3.5 Other Service Types
  • 6.4 Drug Discovery Outsourcing Market, By Therapeutic Area
    • 6.4.1 Oncology
    • 6.4.2 Infectious Diseases
    • 6.4.3 Cardiovascular Diseases
    • 6.4.4 Central Nervous System Disorders
    • 6.4.5 Other Therapeutic Areas

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Drug Discovery Outsourcing Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Drug Discovery Outsourcing market is categorized based on

By Service Type

• Contract Research Organizations
• Contract Manufacturing Organizations
• Contract Development and Manufacturing Organizations
• Contract Sales and Marketing Organizations
• Other Service Types

By Drug Type

• Small Molecule Drugs
• Biologic Drugs
• Other Drug Types

By Therapeutic Area

• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Central Nervous System Disorders
• Other Therapeutic Areas

By User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Covance Inc.
• Charles River Laboratories International, Inc.
• PPD, Inc.
• IQVIA Holdings Inc.
• Syneos Health, Inc.
• Parexel International Corporation
• Medpace, Inc.
• WuXi AppTec
• Envigo
• Lonza Group AG
• Evotec SE
• Catalent, Inc.
• Clinical Research Services, Inc.
• Pharmaron Beijing Co., Ltd.
• Charles River Labs